Simplify Logo
Philips

Philips

Manufactures sleep therapy and respiratory devices

Modality Sales Specialist - Diagnostic Cardiology Solutions

Full-Time
£40.5k - £63.6k/yr

+ Bonus incentive

Mid
Bachelor's
Remote in UK
Hybrid

Remote within the UK, with travel up to 60% to customers in the Midlands and South West.

About the job

Requirements
  • A minimum Bachelor's Degree.
  • A clinical background with a keen interest in Cardiology and familiarity with patient monitoring concepts, such as experience as a Nurse or Operating Department Practitioner.
  • The ability to build rapport and develop key stakeholder relationships.
  • The ability to work toward sales targets.
  • A customer-driven approach and willingness to engage in face-to-face customer interactions.
  • A standard Disclosure and Barring Service criminal record check is required because the role involves working in a healthcare environment.
Responsibilities
  • Execute commercial activities for the Diagnostic Cardiology Solutions portfolio in the UK, driving business growth and collaborating with Account Managers.
  • Sell the Diagnostic Cardiology Solutions portfolio with District teams to achieve annual Order Intake and Sales targets.
  • Analyze the diagnostic electrocardiography landscape, including competition, customer needs, trends, technological innovation, and reimbursement.
  • Collaborate within the team of Modality Sales Specialists for Healthcare and Analytics and Monitoring.
  • Serve as the subject matter expert for the broader Sales team on Diagnostic Cardiology Solutions.
  • Participate in relevant Diagnostic Cardiology Solutions launch teams and localize marketing assets with the Europe Ambulatory Monitoring Device Marketing Specialist and UK Marketing team.
  • Represent the UK and Ireland Zone within the Europe market for Diagnostic Cardiology Solutions and ensure Europe business, marketing, and commercial plans incorporate UK requirements for annual key performance indicators.
  • Develop and execute strategic and tactical plans by identifying new business opportunities and capturing, assessing, and acting on win/loss analysis.
  • Align on local pricing and support Commercial Policy escalations.
  • Collaborate with the Philips Capability Centre to ensure customer orders are fulfilled.
  • Support large and strategic deals in the UK, including strategic accounts and large strategic partnership opportunities, with District teams.
  • Support strategic activities with framework contacts, including NHS Supply Chain and other important frameworks.
  • Work from home while travelling up to 60% to meet customers in the Midlands and South West UK.
Desired Qualifications
  • A clinical background with a keen interest in Cardiology and familiarity with patient monitoring concepts, such as experience as a Nurse or Operating Department Practitioner.

About the company

Philips Respironics designs sleep and respiratory care devices, including CPAP and BiPAP machines, ventilators, and oxygen concentrators, plus related systems. These devices deliver regulated air pressure, support or assist breathing, and provide concentrated oxygen, often paired with software and data tools for monitoring. The division differentiates itself through its long history within Philips and its integrated ecosystem that connects devices with analytics and clinical support across hospital, clinic, and home settings. Its goal is to improve quality of life and clinical outcomes for people with sleep and respiratory conditions by offering reliable devices, patient support, and data-driven care.

Company Size

N/A

Company Stage

Acquired

Total Funding

$164.7M

Headquarters

Murrysville, Pennsylvania

Founded

1891

Simplify Jobs

Simplify's Take

What believers are saying

  • More than 99% of registered CPAP and BiPAP recalls were remediated globally by December 2025.
  • Philips reported Q1 2026 connected care growth and reiterated full-year guidance in May.
  • Respironics-related charges fell to EUR 209 million in 2025 after major settlements finalized.

What critics are saying

  • FDA consent decree still bars new U.S. CPAP and BiPAP sales in 2026.
  • Repeated FDA noncompliance can keep Philips Respironics locked out of the U.S. market indefinitely.
  • The 2021 recall remains active; ventilator remediation and lawsuits keep liability and scrutiny alive.

What makes Philips unique

  • Philips Respironics services recalled U.S. devices and sells parts under the 2024 consent decree.
  • Outside the U.S., Philips Respironics still sells sleep and respiratory devices in 2026.
  • Its 15-million-device installed base gives it unmatched service reach and replacement leverage.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Health Savings Account/Flexible Spending Account

Company News

PR Newswire
May 28th, 2026
Remote patient monitoring market to reach $117.9B by 2033 amid digital healthcare transformation

The global remote patient monitoring market is expected to grow from $67.3 billion in 2026 to $117.9 billion by 2033, registering a CAGR of 8.3%. Growth is driven by rising chronic disease prevalence, expanding telehealth services and increasing demand for home-based healthcare solutions. Devices and hardware account for nearly 38% of market share, led by connected blood pressure monitors, glucometers and wearable health trackers. North America holds approximately 41% of the global market, supported by strong digital healthcare infrastructure and favourable reimbursement policies. Asia Pacific is emerging as the fastest-growing region, driven by healthcare digitisation, telemedicine expansion and rising smartphone penetration. Leading players include Philips Healthcare, Medtronic, GE HealthCare and Abbott Laboratories, focusing on AI integration and cloud connectivity to enhance remote care delivery.

HIT Consultant
Apr 12th, 2024
Philips Respironics Reaches Final Agreement With Us Regulators On Sleep Apnea Device Recall

<img src="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp" alt="Philips Respironics Reaches Final Agreement with US Regulators on Sleep Apnea Device Recall. " class="wp-image-78777" srcset="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp 700w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-300x161.webp 300w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-290x155.webp 290w" sizes="(max-width: 700px) 100vw, 700px">What You Should Know: – Philips Respironics, a subsidiary of Royal Philips, has finalized a consent decree with the US Department of Justice (DOJ) and Food and Drug Administration (FDA) to address issues raised during a 2021 inspection of a Philips facility in Pennsylvania.– The agreement focuses on Philips Respironics’ operations in the US, particularly regarding the recall of certain sleep and respiratory care devices.– The company’s focus will now be on completing remediation efforts, ensuring patient safety, and regaining regulatory approval to resume sales of new devices in the US.Focus on Remediation and ComplianceThe consent decree outlines a roadmap for Philips Respironics to:Prioritize Recall Remediation: Philips will continue efforts to remediate millions of sleep apnea and respiratory care devices recalled in June 2021 due to potential health risks associated with degraded sound abatement foam.Independent Oversight: Independent experts will be brought in to review recall remediation efforts and ensure Philips Respironics’ business operations comply with FDA regulations.Continued Patient Support: Philips Respironics can continue servicing existing devices in the hands of patients and healthcare providers. Additionally, they can sell accessories, consumables, and replacement parts for these devices.Sales Restrictions Remain in USThe FDA has not yet authorized Philips Respironics to resume sales of new CPAP, BiPAP, or other respiratory care devices in the US. This restriction will remain in place until Philips meets the requirements outlined in the consent decree.Global Sales Continue with RestrictionsPhilips Respironics can continue to sell new devices, accessories, consumables, and replacement parts outside the US,  subject to specific requirements.Safety of Devices with New Foam ConfirmedPhilips Respironics has conducted tests on devices using a new silicone sound abatement foam and found no safety issues. Patients can continue to use these devices following the instructions for use.Financial ImpactPhilips anticipates incurring costs associated with remediation activities and profit disgorgement related to US sales. These costs are estimated at 100 basis points in 2024.  The company’s previously announced 2023-2025 financial outlook remains unchanged,  already factoring in the consent decree. “Strengthening patient safety and quality remains Philips’ highest priority and the increased scrutiny will help us to improve even more

Goodrich Pharmacy
Jan 29th, 2024
Phillips Suspends U.S. Sales of CPAP, Ventilator Machines After Recall

Following a recall of millions of its breathing machines that began in mid-2021, Phillips Respironics announced Monday that it would halt sales of all such machines within the United States.

YourLawyer.com
Mar 23rd, 2023
Sleep Apnea Patients Suffer While Waiting To Receive Their Repaired Philips CPAP Machines

In June of 2021, Philips began a recall of over five million of its breathing devices due to toxic fume and substances emanating from the devices’ sound abatement foam.

Digital Journal
Jan 13th, 2023
Ultrasound Market Share | Market | Report | Analysis 2032 | Key Players: Fujifilm Holdings Corporation, Analogic Corporation, Siemens Healthcare among others

February 2019 – Koninklijke Philips launched the EPIQ Elite ultrasound system in the market.